New generation of precision medicine in immuno-oncology,
with proprietary STC platform, designed to generate
first-in-class, proteomic-driven cancer vaccines.
Anticipating tumor’s evolution in cold solid tumors,
which is currently the biggest unmet need in oncology.
90% of patients currently undergoing treatment for solid tumors will experience treatment failure and relapse within the next 5 years.
This represents 10 million patients annually,
and is projected to increase by 70% by 2045.
It constantly adapts and evolves to evade the immune system.
CHARACTERIZED BY MULTI-OMICS ANALYSIS
REGARDLESS OF THEIR EVOLUTION
+150 PRECISION CANCER-RELATED
TARGETS
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
See Video here
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
REMAINS A HUGE UNMET NEED WORLDWIDE
incidence
mortality
REMAINS A HUGE UNMET NEED WORLDWIDE
incidence
mortality
We are backed by internationally recognized key scientific opinion leaders. They act as strategic advisors to ensure validation process robustness, and as main ambassadors of our technology, significantly contributing to our publications.
Our team is driven by passion and dedication, working in collaboration to bring innovative therapeutic solutions to patients.
With the support of
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
